Clinical Trials
67 trialsPazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
National Cancer Institute (NCI)
PLANE-PC
University of Michigan Rogel Cancer Center
DeLLphi-307
Amgen
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
Entinostat Neuroendocrine (NE) Tumor
Columbia University
NETTER-P
Advanced Accelerator Applications
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Open-Label Surufatinib in European Patients With NET
Hutchmed
TALENT
Grupo Espanol de Tumores Neuroendocrinos
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
DUNE
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Case Comprehensive Cancer Center
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
EVACEL
Federation Francophone de Cancerologie Digestive
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
ALpha-T
Hoffmann-La Roche
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Telotristat With Lutathera in Neuroendocrine Tumors
University of Kentucky
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Pembro NEC
University of Utah
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Ochsner Health System
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Fox Chase Cancer Center
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Ipsen
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
University of Iowa
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
ATLANT
Ipsen
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Institutes of Health Clinical Center (CC)
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Study of Panobinostat in Patients With Neuroendocrine Tumors
University of Wisconsin, Madison
Lithium for Low-Grade Neuroendocrine Tumors
University of Wisconsin, Madison
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
Pazopanib as Single Agent in Advanced NETs
Grupo Espanol de Tumores Neuroendocrinos
SONNET
Ipsen
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
University of California, San Francisco
Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors
University Health Network, Toronto
RAMSETE/CDE16
Novartis
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute